blood disorder
Novartis presents strong results in rare blood disorder trials
June 10, 2016Medical Communications, Research and Development Jakavi, Novartis, Revolade, blood disorder
Novartis has released data from two late-stage trials for rare blood disorders, which showed that Javi (ruxolitinib) is superior to …
Amgen’s drug reduces rates of bleeding in rare childhood disorder
April 21, 2016Research and Development, Sales and Marketing Amgen, blood disorder, children, nplate, paediatric, platelet, rare, romisplostim
Amgen (NASDAQ: AMGN) has announced the results of a Phase III trial, published in The Lancet, which shows that Nplate …
Novartis receives EU approval for blood disorder treatment in children
April 7, 2016Research and Development, Sales and Marketing EMA, EU, ITP, Novartis, Revolade, approval, blood disorder, children, chronic itp
Novartis (NYSE: NVS) has announced that Revolade (eltrombopag) has been approved in the EU for use in paediatric patients aged …
Targacept and Catalyst sign $100 million deal
March 9, 2015Research and Development, Sales and Marketing CB 813d, PF-05280602, Targecept, blood disorder, catalyst biosciences
Targacept and Catalyst Biosciences have signed a merger agreement which will see them develop new treatment options for patients with …
